INARI MEDICAL INC (NARI)

US45332Y1091 - Common Stock

50.055  +0.3 (+0.61%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

INARI MEDICAL INC

NASDAQ:NARI (11/22/2024, 3:25:59 PM)

50.055

+0.3 (+0.61%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-0.4%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.93B
Shares
PEN/A
Fwd PE350.53
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NARI Daily chart

Company Profile

Inari Medical, Inc. operates as a medical device company. The company is headquartered in Irvine, California and currently employs 1,300 full-time employees. The company went IPO on 2020-05-22. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. The company also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.

Company Info

INARI MEDICAL INC

6001 Oak Canyon, Suite 100

Irvine CALIFORNIA 92618

P: 19499234747

CEO: William Hoffman

Employees: 1300

Website: https://www.inarimedical.com

NARI News

News Image4 days ago - Market News VideoFirst Week of January 2025 Options Trading For Inari Medical (NARI)
News Image16 days ago - Inari Medical, Inc.Inari Medical to Participate in the Jefferies London Healthcare Conference
News Image24 days ago - Market News VideoInari Medical Breaks Above 200-Day Moving Average - Bullish for NARI
News Image24 days ago - Inari Medical, Inc.PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism

Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization

News Image24 days ago - Inari Medical, Inc.PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism

Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization

News Image25 days ago - Inari Medical, Inc.Inari Medical Reports Third Quarter 2024 Financial Results

NARI Twits

Here you can normally see the latest stock twits on NARI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example